## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.6% below STRENGTH zone (3.0-6.0%); PEG 35.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bearish (Bullish: 0, Bearish: 4)

**1. Baxter International (BAX) Is Up 7.5% After Class Action Over Infusion Pump Defects Filed**
- Source: Simply Wall Street | 20251216T113300 | Bearish | Relevance: 100%
- Baxter International is facing a class action lawsuit alleging it concealed defects in its Novum LVP infusion pumps and misled investors. This legal action significantly heightens the company's risks, potentially impacting regulatory scrutiny, customer confidence, and its financial flexibility amidst ongoing efforts to reshape its portfolio. Despite these challenges, Baxter's investment narrative projects substantial revenue and earnings growth by 2028, suggesting a potential upside to its current price according to some analyses.

**2. Baxter International (BAX) Is Up 7.5% After Class Action Over Infusion Pump Defects Filed**
- Source: Simply Wall Street | 20251216T110815 | Somewhat-Bearish | Relevance: 100%
- A class action lawsuit has been filed against Baxter International (BAX) by Levi & Korsinsky, LLP, alleging the company concealed serious safety defects in its Novum LVP infusion pumps between February 23, 2022, and October 29, 2025. The lawsuit highlights reported malfunctions, injuries, and deaths linked to the pumps, questioning Baxter's product oversight and investor disclosures. This legal action could significantly impact Baxter's investment narrative, particularly concerning regulatory scrutiny, customer confidence, and financial flexibility while it addresses other balance sheet constraints.

**3. Pomerantz LLP Reminds Shareholders with Losses on their Investment in Baxter International, Inc. – BAX**
- Source: CBS 17 | 20251216T090807 | Bearish | Relevance: 100%
- Pomerantz LLP has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) concerning alleged securities fraud or unlawful business practices. The lawsuit follows a significant drop in Baxter's stock price after the company temporarily paused shipments of its Novum LVP medical device. Investors who purchased Baxter securities during the Class Period are encouraged to seek lead plaintiff status by December 15, 2025.

**4. BAX DEADLINE - FINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Baxter International, Inc. Investors to Participate in the Class Action Lawsuit**
- Source: CBS 42 | 20251216T050727 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Baxter International, Inc. (NYSE:BAX) on behalf of investors who purchased securities between February 23, 2022, and October 29, 2025. The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in its Novum LVP medical devices, which caused widespread malfunctions, serious injuries, and deaths. Investors who suffered losses are encouraged to join the case by December 15, 2025, to potentially be appointed as lead plaintiff.

**5. BAX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BAX**
- Source: GlobeNewswire | 20251216T040756 | Bearish | Relevance: 100%
- The Rosen Law Firm is reminding investors who purchased Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025 lead plaintiff deadline for a securities class action. The lawsuit alleges that Baxter misled investors about systemic defects in its Novum IQ Large Volume Pump, which caused widespread malfunctions and patient risks. Investors are encouraged to contact the firm to potentially join the class action and seek compensation.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.17M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.5x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 27.3% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 35.49 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.8B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.49 |
| Forward P/E | 8.3 |
| Current P/E | 8.1 |
| YoY Growth | -2.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.0% to 2.6% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.4pp (needs >3.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.73x), long-term trend not supportive. RSI neutral at 51. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.65% (CS: 77) | Neutral |
| RSI_14 | 50.7 | Neutral |
| MACD Histogram | 0.18 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.727x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.07
- **Stop Loss:** $17.97 (5.8% risk)
- **Target:** $20.17 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 863
- **Position Value:** $16,457.41
- **Portfolio %:** 16.46%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*